Drug and anti-Drug ELISA Test Kits
Posted by Brandon Savela on Mar 6th 2017
IBL-America is excited to promote our ImmunoGuide research drug monitoring product line. These state-of-the-art ELISA test kits are used for the measurement of drug and anti-drug concentrations for research applications. The product range is covering the following parameters:
| Infliximab | Etanercept | Adalimumab | Bevacizumab |
| Trastuzumab | Rituximab | Golimumab | Tocilizumab |
| Certolizumab Pegol | Omalizumab | Cetuximab | Aflibercept |
| *Vedulizumab | *Ustekinumab | *Nivolumab | *Daratumumab |
Our quantitative drug assays use the catcher on the microtiter plate as either the target molecule (product code AA) or a monoclonal antibody (mAb) from our own development (product code AB). In both cases the results represent the free drug concentration. In the case of AB-coded products the mAb specifically binds the drug without any cross reaction to other drugs directed against the same target. A separate 2-level control set is available upon request for all drug assays.
The design of the semi-quantitative anti-drug ELISAs allow the use of a confirmatory reagent for the verification of positive results so that false positives easily can be excluded. The results of all the Anti-drug assays are given in arbitrary units and represent either the free (product code BB) or the total (product code TA) antibody concentration. The Infliximab Total antibody concentration assay is measuring Anti-Infliximab (ATI) in the 20 fold excess of the drug Infliximab. More TA assays are under development.
Please contact us to collaborate with mAb drug manufacturers in the early stage of the product development. The modular kit design allows a quick development of any new drug or anti-drug ELISA.
More information about these ImmunoGuide products is available here.
* To be released soon
